Haemonetics’s 21.4% return over the past six months has outpaced the S&P 500 by 15.6%, and its stock price has climbed to $65 ...

Blood products company Haemonetics (NYSE:HAE). in Q4 CY2025, but sales fell by 2.7% year on year to $339 million. Its non-GAAP profit of $1.31 per share was 4.8% above analysts’ consensus estimates.

Why Haemonetics Is On Investors’ Radar Haemonetics (HAE) has drawn attention after recent trading left the shares around $57.76, with negative returns over the month and past 3 months prompting ...

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a ...

Haemonetics (NYSE: HAE) announced that it received FDA approval for its NexSys PCS plasma collection system with Persona PLUS ...

BOSTON, Feb. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Haemonetics (HAE), which belongs to the Zacks ...

Haemonetics will shell out up to 185 million euros ($216 million) to acquire Vivasure Medical, a Galway, Ireland-based medtech that makes arterial closure devices. Boston-based Haemonetics, which is ...

Frank Chan joins Haemonetics as Executive Vice President, Chief Operating Officer; Roy Galvin named Executive Vice President, Chief Commercial Officer As Chief Operating Officer, Chan will direct ...